Helix Acquisition III (HLXC)
Market Price (5/30/2026): $10.25 | Market Cap: $168.3 MilSector: Financials | Industry: Multi-Sector Holdings
Helix Acquisition III (HLXC)
Market Price (5/30/2026): $10.25Market Cap: $168.3 MilSector: FinancialsIndustry: Multi-Sector Holdings
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Low stock price volatilityVol 12M is 7.0% | Trading close to highsDist 52W High is -0.9%, Dist 3Y High is -0.9% Weak multi-year price returns2Y Excs Rtn is -44%, 3Y Excs Rtn is -83% | Key risksHLXC key risks include [1] failure to complete a business combination, Show more. |
| Low stock price volatilityVol 12M is 7.0% |
| Trading close to highsDist 52W High is -0.9%, Dist 3Y High is -0.9% |
| Weak multi-year price returns2Y Excs Rtn is -44%, 3Y Excs Rtn is -83% |
| Key risksHLXC key risks include [1] failure to complete a business combination, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 5/1/2026
Helix Acquisition III (HLXC) stock has remained largely at the same level since 1/31/2026 because of the following key factors:
1. Absence of a Definitive Business Combination Agreement.
Helix Acquisition III (HLXC) is a Special Purpose Acquisition Company (SPAC) that completed its initial public offering (IPO) on January 26, 2026, raising $172.5 million by offering shares at $10.00 each. As a SPAC, its primary purpose is to merge with or acquire an operating company. Until a definitive business combination agreement is announced, SPACs typically trade around their initial trust value, usually the $10.00 IPO price. There have been no announcements of a target acquisition or merger since January 31, 2026, keeping the stock price stable and near its IPO value. The stock's all-time high was $10.35 on February 1, 2026, and its all-time low was $10.11 on March 12, 2026, demonstrating minimal fluctuation.
2. Low Volatility Inherent to Pre-Deal SPACs Without Warrants.
HLXC's stock has exhibited low price volatility since its listing, remaining largely at the same level. This stability is characteristic of pre-deal SPACs, as the cash raised during the IPO is held in a trust account, providing a floor for the stock price. Furthermore, unlike many SPAC offerings, Helix Acquisition III's IPO was a stock-only offering and did not include warrants, which often contribute to increased volatility in other SPACs as they represent an additional speculative element.
Show more
Helix Acquisition III (HLXC) stock has remained largely at the same level since 1/31/2026 because of the following key factors:
1. Absence of a Definitive Business Combination Agreement.
Helix Acquisition III (HLXC) is a Special Purpose Acquisition Company (SPAC) that completed its initial public offering (IPO) on January 26, 2026, raising $172.5 million by offering shares at $10.00 each. As a SPAC, its primary purpose is to merge with or acquire an operating company. Until a definitive business combination agreement is announced, SPACs typically trade around their initial trust value, usually the $10.00 IPO price. There have been no announcements of a target acquisition or merger since January 31, 2026, keeping the stock price stable and near its IPO value. The stock's all-time high was $10.35 on February 1, 2026, and its all-time low was $10.11 on March 12, 2026, demonstrating minimal fluctuation.
2. Low Volatility Inherent to Pre-Deal SPACs Without Warrants.
HLXC's stock has exhibited low price volatility since its listing, remaining largely at the same level. This stability is characteristic of pre-deal SPACs, as the cash raised during the IPO is held in a trust account, providing a floor for the stock price. Furthermore, unlike many SPAC offerings, Helix Acquisition III's IPO was a stock-only offering and did not include warrants, which often contribute to increased volatility in other SPACs as they represent an additional speculative element.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
1/31/2026 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HLXC | 0.0% | |
| Market (SPY) | 9.6% | 0.5% |
| Sector (XLF) | -3.0% | 2.6% |
Fundamental Drivers
nullnull
Market Drivers
10/31/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HLXC | ||
| Market (SPY) | 11.5% | 0.9% |
| Sector (XLF) | -0.7% | 0.5% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2025 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HLXC | ||
| Market (SPY) | 38.0% | 0.9% |
| Sector (XLF) | 7.4% | 0.5% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/29/2026| Return | Correlation | |
|---|---|---|
| HLXC | ||
| Market (SPY) | 89.0% | 0.9% |
| Sector (XLF) | 63.2% | 0.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HLXC Return | - | - | - | - | - | -0% | -0% |
| Peers Return | 79% | -36% | -49% | 1% | -24% | 232% | 50% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| HLXC Win Rate | - | - | - | - | - | 40% | |
| Peers Win Rate | 50% | 25% | 33% | 42% | 17% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| HLXC Max Drawdown | - | - | - | - | - | - | |
| Peers Max Drawdown | -31% | -41% | -60% | -44% | -45% | -1% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BEBE, AACO, ACAA, AEAQ, ALOV.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/29/2026 (YTD)
How Low Can It Go
HLXC has limited trading history. Below is the Financials sector ETF (XLF) in its place.
| Event | XLF | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -15.5% | -18.8% |
| % Gain to Breakeven | 18.4% | 23.1% |
| Time to Breakeven | 80 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -10.7% | -9.5% |
| % Gain to Breakeven | 12.0% | 10.5% |
| Time to Breakeven | 26 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -16.1% | -6.7% |
| % Gain to Breakeven | 19.1% | 7.1% |
| Time to Breakeven | 270 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -22.3% | -24.5% |
| % Gain to Breakeven | 28.6% | 32.4% |
| Time to Breakeven | 467 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -42.8% | -33.7% |
| % Gain to Breakeven | 74.8% | 50.9% |
| Time to Breakeven | 289 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -19.7% | -19.2% |
| % Gain to Breakeven | 24.5% | 23.8% |
| Time to Breakeven | 123 days | 105 days |
In The Past
State Street Financial Select Sector SPDR ETF's stock fell -15.5% during the 2025 US Tariff Shock. Such a loss loss requires a 18.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
HLXC has limited trading history. Below is the Financials sector ETF (XLF) in its place.
| Event | XLF | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -22.3% | -24.5% |
| % Gain to Breakeven | 28.6% | 32.4% |
| Time to Breakeven | 467 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -42.8% | -33.7% |
| % Gain to Breakeven | 74.8% | 50.9% |
| Time to Breakeven | 289 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -21.4% | -12.2% |
| % Gain to Breakeven | 27.3% | 13.9% |
| Time to Breakeven | 272 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -26.1% | -17.9% |
| % Gain to Breakeven | 35.3% | 21.8% |
| Time to Breakeven | 162 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -78.3% | -53.4% |
| % Gain to Breakeven | 359.8% | 114.4% |
| Time to Breakeven | 2329 days | 1085 days |
In The Past
State Street Financial Select Sector SPDR ETF's stock fell -15.5% during the 2025 US Tariff Shock. Such a loss loss requires a 18.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Helix Acquisition III (HLXC)
We are a blank check company incorporated on September 10, 2025, as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. --- Consistent with our business strategy, we expect to identify companies that have compelling growth potential and a combination of the following characteristics. We will seek to acquire companies or assets with a significant share of the following characteristics: • rigorous science that includes a unique insight or a novel approach coupled to targets with clear, simple therapeutic rationale; • compelling data indicating a drug candidate or platform is likely to generate a differentiated therapeutic for patients suffering from serious disease and with unmet need; • nimble critical path to generate data that will advance one or more drug candidates through research, clinical, or regulatory milestones and value step-ups; • the right management team with requisite experience and skills to develop and commercialize the most compelling drug candidates and that will benefit from our capital, advice, and network; and • an attractive valuation that traces to being overlooked as too early, misunderstood due to complex science, or undercapitalized and that can offer near-term liquidity and significant upside for investors. Any evaluation relating to the merits of a particular initial business combination may be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may deem relevant. We may decide to enter into our initial business combination with a target business that does not meet the above criteria and guidelines. Our executive offices are located in Boston, MA.
AI Analysis | Feedback
null
AI Analysis | Feedback
- Initial Business Combination: Helix Acquisition III's primary service is to complete a merger, share exchange, asset acquisition, or similar business combination with one or more private businesses, effectively taking them public.
AI Analysis | Feedback
Helix Acquisition III (HLXC) is a Special Purpose Acquisition Company (SPAC), also known as a blank check company. Its stated purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It has not yet identified a target company and does not currently sell any products or services.
Therefore, Helix Acquisition III (HLXC) does not have any major customers in the traditional sense. Its primary function is to acquire another company, not to sell goods or services to other companies or individuals.
AI Analysis | Feedback
```html null ```AI Analysis | Feedback
Bihua Chen, Chief Executive Officer and Chairperson
Bihua Chen is the founder and Managing Member of Cormorant Asset Management, a healthcare investment firm. She has a history of managing companies through her involvement with previous Special Purpose Acquisition Companies (SPACs). Her prior SPACs include Helix Acquisition II, which completed its merger with oncology biotech BridgeBio Oncology Therapeutics in August 2025, and Helix Acquisition, which merged with biotech MoonLake Immunotherapeutics in April 2022. BridgeBio Oncology Therapeutics' shares increased 13% from its $10 offer price, and MoonLake Immunotherapeutics' shares rose 56% following its merger. Ms. Chen also serves as a Director for Nexo Therapeutics, Inc. and nChroma Bio.
Caleb Tripp, Chief Financial Officer and Chief Operating Officer
Caleb Tripp also holds the position of Chief Financial Officer for Cormorant Asset Management, the affiliate sponsoring Helix Acquisition III.
AI Analysis | Feedback
For Helix Acquisition III (HLXC), a blank check company, the key risks to its business are primarily related to its fundamental purpose of completing a business combination:- Inability to Complete an Initial Business Combination: Helix Acquisition III's core business is to effect a merger, share exchange, asset acquisition, or similar business combination. A significant risk is the potential failure to identify and successfully complete an initial business combination within the typical timeframe allotted for such entities, which could lead to the company's liquidation. In such a scenario, investors would likely receive back their initial capital, possibly without any gains and after accounting for operational costs.
- Difficulty in Identifying and Acquiring a Suitable Target Business: The company has not yet selected any specific business combination target. Despite its intent to focus on healthcare or healthcare-related industries, there is a risk of not being able to identify a suitable business that meets its outlined criteria for growth potential, rigorous science, compelling data, and attractive valuation. Even after identification, successfully negotiating and acquiring a target can be challenging, potentially leading to deal failure or dissolution.
AI Analysis | Feedback
null
AI Analysis | Feedback
nullAI Analysis | Feedback
Helix Acquisition III (HLXC) is a blank check company that currently has no operations or revenue. Its future revenue growth over the next 2-3 years will be entirely dependent on its ability to complete an initial business combination. The expected drivers of future revenue growth for HLXC are:- Successful Completion of an Initial Business Combination: As a special purpose acquisition company (SPAC), HLXC's primary objective is to merge with or acquire an existing business. Revenue growth for HLXC will only commence after it successfully identifies and completes an acquisition, at which point the acquired entity's revenues will be reflected.
- Strategic Selection of a High-Growth Target Company: HLXC intends to focus on healthcare or healthcare-related industries, seeking companies with compelling growth potential and rigorous science. The inherent revenue growth drivers of the acquired company, such as new product launches, expansion into new markets, or growth of existing products, will become the drivers for the combined entity.
- Leveraging Management Expertise and Capital for Accelerated Growth: HLXC's management team plans to utilize their expertise, capabilities, capital, advice, and network to benefit the acquired company and enhance its growth trajectory, aiming to create long-term shareholder value. This strategic support is expected to accelerate the revenue growth of the merged business.
AI Analysis | Feedback
Share Issuance
- Helix Acquisition III completed its initial public offering (IPO) on January 26, 2026, selling 17,250,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $172,500,000.
- The IPO included the full exercise of the underwriters' over-allotment option for 2,250,000 additional shares.
- Concurrently with the IPO, the company completed a private placement of 497,500 Class A ordinary shares to its sponsor, Helix Holdings III LLC, at $10.00 per share, raising $4,975,000.
Inbound Investments
- Helix Holdings III LLC, the company's sponsor, made an inbound investment of $4,975,000 by purchasing 497,500 Class A ordinary shares in a private placement concurrent with the IPO.
Trade Ideas
Select ideas related to HLXC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | EEFT | Euronet Worldwide | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04242026 | HOMB | Home BancShares | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 1.5% | 1.5% | 0.0% |
| 03312026 | HBAN | Huntington Bancshares | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 7.1% | 7.1% | 0.0% |
| 03312026 | NP | Neptune Insurance | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 3.9% | 3.9% | 0.0% |
| 03272026 | JKHY | Jack Henry & Associates | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.3% | 0.3% | -4.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.98 |
| Mkt Cap | 0.3 |
| Rev LTM | - |
| Op Inc LTM | - |
| FCF LTM | - |
| FCF 3Y Avg | - |
| CFO LTM | - |
| CFO 3Y Avg | - |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | - |
| Rev Chg 3Y Avg | - |
| Rev Chg Q | - |
| QoQ Delta Rev Chg LTM | - |
| Op Inc Chg LTM | - |
| Op Inc Chg 3Y Avg | - |
| Op Mgn LTM | - |
| Op Mgn 3Y Avg | - |
| QoQ Delta Op Mgn LTM | - |
| CFO/Rev LTM | - |
| CFO/Rev 3Y Avg | - |
| FCF/Rev LTM | - |
| FCF/Rev 3Y Avg | - |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | - |
| P/Op Inc | - |
| P/EBIT | - |
| P/E | - |
| P/CFO | - |
| Total Yield | - |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | - |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.4% |
| 3M Rtn | -0.6% |
| 6M Rtn | -0.4% |
| 12M Rtn | -0.4% |
| 3Y Rtn | -0.4% |
| 1M Excs Rtn | -5.8% |
| 3M Excs Rtn | -10.8% |
| 6M Excs Rtn | -12.4% |
| 12M Excs Rtn | -29.1% |
| 3Y Excs Rtn | -83.2% |
Earnings Returns History
Updated 5/29/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 5/29/2026